CytomX Therapeutics, Inc.

Informe acción NasdaqGS:CTMX

Capitalización de mercado: US$110.4m

Dividendos de CytomX Therapeutics

Dividendo controles de criterios 0/6

CytomX Therapeutics no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

n/a

Ratio de pago

Rentabilidad media de la industria2.9%
Próxima fecha de pago de dividendosn/a
Fecha ex dividendon/a
Dividendo por acciónn/a
Beneficios por acción-US$0.0084
Rentabilidad por dividendo prevista a 3 añosn/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

Apr 27
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Not Doing Enough For Some Investors As Its Shares Slump 27%

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 25

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Jan 19
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%

There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

Nov 26
There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise

We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Nov 17
We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely

Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 29
Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts

Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Feb 13
Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

CytomX Therapeutics to cut workforce by about 40%

Jul 13

CytomX says phase 2 study of breast cancer antibody treatment met main goal

Jul 06

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

CytomX: Pullbacks Are Opportunities

Dec 14

CytomX: Solving A Critical Problem In The High-Value ADC Space

Sep 15

We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Aug 11
We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Checking In On CytomX Therapeutics

Jun 13

Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

Jun 10
Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

CytomX EPS beats by $0.06, misses on revenue

May 06

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%

Mar 25
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%

Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today?

Feb 02
Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today?

How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?

Dec 29
How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?

Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Dec 03
Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de CTMX han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de CTMX han aumentado.


Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de CytomX Therapeutics vs. Mercado
¿Cómo se compara la rentabilidad por dividendo de CTMX con la del mercado?
SegmentoRentabilidad por dividendo
Empresa (CTMX)n/a
Suelo de mercado 25% (US)1.6%
Techo de mercado 25% (US)4.8%
Media de la industria (Biotechs)2.9%
Previsión de analistas en 3 años (CTMX)n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de CTMX en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de CTMX en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.


Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de CTMX para determinar si sus pagos de dividendos están cubiertos por los beneficios.


Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que CTMX no ha comunicado ningún pago.


Discover strong dividend paying companies